Cronos Group Inc.
NASDAQ:CRONDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $1.16B
- Beta
- 1.25
- P/E (TTM)
- -488.3
- EPS (TTM)
- -$0.01
Volume 1.13M
Average 1.51M
CRON Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Cronos Group Inc.NASDAQ: CRON
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $19.9M rose 11.8% year over year, ahead of the -31.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 115.9% from the prior quarter. Over 3 fiscal years it compounded at -14.4% a year.
Context
- Operating expenses amounted to 53.3% of revenue in FY2025, down 33.2 pp from a year earlier.
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +11.8% holds above the trailing-twelve-month pace of -31.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 79.54M USD
- Year-over-year change
- -21.8%
- 4-year CAGR
- -26.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 79.54M | -21.8% |
| FY2024 | 2024-12-31 | 101.73M | +5.2% |
| FY2023 | 2023-12-31 | 96.71M | -23.8% |
| FY2022 | 2022-12-31 | 126.86M | -53.8% |
| FY2021 | 2021-12-31 | 274.38M | — |
Operating Expenses vs competitors
How CRON compares with its peers on the latest reported figures
- CRON's LTM Mar 2026 operating expenses of $67.79M is the 10th highest of the 11 companies compared; the peer median is $266.08M.
- Its year-over-year change of -31.6% is the lowest of 11, against a peer median of +18.2%.
- Operating expenses amounts to 33.0% of revenue for CRON, versus a peer median of 45.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $560.33M | -11.1% | +10.1% | 76.2% | |
| LTM Mar 2026 | $341.3M | -22.9% | -4.1% | 32.7% | |
| LTM Aug 2026 | $317.52M | +142.5% | +109.8% | 45.2% | |
| LTM Mar 2026 | $293.27M | +21.6% | +16.2% | 36.8% | |
| LTM Mar 2026 | $270.62M | -24.2% | +22.1% | 132.1% | |
| LTM Jun 2026 | $261.54M | +14.7% | +83.3% | 249.1% | |
| LTM Mar 2026 | $224.39M | +28.7% | +15.1% | 31.1% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $168.68M | +90.5% | +3360.1% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $141.71M | +52.6% | +129.5% | 708.6% |
| LTM Mar 2026 | $67.79M | -31.6% | -14.4% | 33.0% | |
| LTM Mar 2026 | $38.34M | +9.1% | +14.2% | 44.4% | |
| Peer median (excluding CRON) | $266.08M | +18.2% | +19.1% | 45.2% | |
Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 64.56M | 86.75M | 87.24M | 117.62M | 149.15M |
| Cost of Revenue | 82.15M | 71.31M | 75.33M | 92.42M | 87.45M |
| Gross Profit | (17.59M) | 15.44M | 11.91M | 25.2M | 61.7M |
| Gross Margin | -27.3% | 17.8% | 13.7% | 21.4% | 41.4% |
| Research & Development | 21.84M | 13.13M | 5.84M | 4.23M | 4.45M |
| Selling, General & Admin | 121.68M | 100.73M | 80.93M | 76.82M | 63.76M |
| Operating Expenses | 274.38M | 126.86M | 96.71M | 101.73M | 79.54M |
| Depreciation & Amortization | 15.4M | 13.12M | 8.11M | 9.34M | 14.48M |
| EBITDA | (150.13M) | (91.27M) | (71.8M) | (50.21M) | (3.36M) |
| EBITDA Margin | -232.5% | -105.2% | -82.3% | -42.7% | -2.3% |
| Operating Income | (291.97M) | (111.43M) | (84.8M) | (76.53M) | (17.84M) |
| Operating Margin | -452.2% | -128.4% | -97.2% | -65.1% | -12.0% |
| Interest Income | 9.07M | 22.51M | 51.24M | 52.02M | 40.66M |
| Interest Expense | 27K | 13K | 0 | 0 | 0 |
| Other Income / Expenses | 163.46M | (9.58M) | 11.13M | 113.12M | 419.21K |
| Income Before Tax | (128.51M) | (121M) | (73.67M) | 36.59M | (17.42M) |
| Pre-Tax Margin | -199.1% | -139.5% | -84.4% | 31.1% | -11.7% |
| Income Tax Expense | (431K) | 34.18M | (3.23M) | (3.44M) | (14.44M) |
| Net Income | (396.11M) | (168.73M) | (73.96M) | 41.08M | (9.61M) |
| Net Margin | -613.5% | -194.5% | -84.8% | 34.9% | -6.4% |
| EPS (Basic) | (1.07) | (0.45) | (0.19) | 0.11 | (0.03) |
| EPS (Diluted) | (1.07) | (0.45) | (0.19) | 0.11 | (0.03) |
| Weighted Avg Shares | 370.39M | 376.96M | 403.4M | 382.06M | 385.31M |
| Weighted Avg Shares (Diluted) | 370.39M | 376.96M | 380.97M | 385.56M | 385.31M |
Cronos Group Inc.
NASDAQ:CRON
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.